(Schaumburg, IL…May 28, 2014). Cancer Treatment Centers of America® (CTCA) today announced the appointment of Maurie Markman, MD, as President of the company’s Medicine & Science unit, in which capacity he will be responsible for advancing the organization’s overall commitment to clinical excellence, innovation, safety, and patient satisfaction. Dr. Markman served most recently as Senior Vice President of Clinical Affairs & National Director of Medical Oncology at CTCA®.
“We are delighted to have Dr. Markman assume the leadership of this vitally important group within Cancer Treatment Centers of America,” commented CTCA President and CEO Gerard van Grinsven. His expertise in the field of medical oncology and clinical research, combined with his pioneering work in the emerging field of advanced genomic testing, will ensure we continue to deliver the very best clinical care to our patients.”
In his new role, Dr. Markman will assume oversight of the CTCA national clinical team, with a focus on the application of all clinical and translational research to patient care. An expert in research on gynecologic malignancies, new drug development, and novel management strategies, Dr. Markman served in a variety of clinical leadership and academic positions at some of the country’s leading cancer institutions prior to joining CTCA in 2010, including The Cleveland Clinic, the University of Texas - MD Anderson Cancer Center, The Ohio State University, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, and the University of California San Diego School of Medicine.
A graduate of the University of Southern California, Dr. Markman received his medical degree from New York University (NYU) School of Medicine, as well as a Master of Science in Health Policy and Management from the NYU Graduate School of Public Administration. After completing his internship and residency in internal medicine at Bellevue Hospital - New York University Medical Center, he served as a Clinical Associate of the National Cancer Institute’s Immunology Branch, then as an Assistant Professor of Oncology and Medicine at The Johns Hopkins Hospital.
“I am honored to have been selected to lead the impressive clinical team at CTCA,” said Markman, “and look forward to lending my expertise to the continued advancement of the exceptional quality of care we deliver to our patients.”
About Cancer Treatment Centers of America®
Cancer Treatment Centers of America Global, Inc. (CTCA), headquartered in Boca Raton, Fla., is a national network of five hospitals that serves adult patients who are fighting cancer. CTCA® offers an integrative approach to care that combines advancements in genomic testing and precision cancer treatment, surgery, radiation, immunotherapy and chemotherapy, with evidence-based supportive therapies designed to help patients physically and emotionally by enhancing their quality of life while managing side effects both during and after treatment. CTCA serves patients from around the world at its hospitals in Atlanta, Chicago, Philadelphia, Phoenix and Tulsa. Consistently rated among U.S. hospitals that deliver the highest quality of care and patient experience, CTCA provides patients and their families with comprehensive information about their treatment options and encourages their active participation in treatment decisions. For more information, visit cancercenter.com, Facebook.com/cancercenter and Twitter.com/cancercenter.